How to Select Patients for Aripiprazole 2-Month Maintenance in Schizophrenia
How do clinicians identify which adults with schizophrenia are appropriate candidates for aripiprazole 2-month ready-to-use 960 mg maintenance treatment?
Adults with schizophrenia who are already symptomatically stable may benefit from a longer-interval long-acting injectable if they can safely transition to or continue aripiprazole maintenance treatment. This guide applies to maintenance decision-making rather than acute stabilization and focuses on the patient characteristics used in the trial.
-
Confirm that the patient fits a maintenance-treatment population
Use this approach for adults aged 18 to 64 years with a current DSM-5 diagnosis of schizophrenia. In the study, patients also had to be in good physical health, have a body mass index of 18 to 35 kg/m2, and be clinically stable on an atypical antipsychotic for at least 2 months before screening.
-
Verify prior aripiprazole tolerability or establish it
Confirm a prior history of tolerating oral aripiprazole and/or aripiprazole once-monthly 400 mg if available. If the patient does not have a history of tolerating aripiprazole, the study established tolerability by giving 10 mg oral aripiprazole on 3 consecutive days, for a total of 30 mg, in addition to the patient's current oral antipsychotic.
-
Exclude patients with recent substance use disorder or positive drug testing concerns
Do not apply this study-based workflow to patients with DSM-5 substance use disorder within the past 180 days. Patients were also excluded for a positive test for drugs of abuse, except nicotine, alcohol, and marijuana when there was a clinical rationale, review of use patterns and frequency, and justification for protocol compliance.
-
Screen for acute psychiatric instability and suicide risk
Do not use this trial population as a model for patients in current acute relapse of schizophrenia or with treatment resistance to an atypical antipsychotic. Patients were also excluded if they were judged to have significant suicide risk, including a yes response to Columbia-Suicide Severity Rating Scale questions 4 or 5 for current or past-6-month active suicidal ideation with some intent to act or with specific plan and intent.
-
Review diagnoses, neurologic history, and interacting medications
The trial excluded patients with a current DSM-5 diagnosis other than schizophrenia, history of neuroleptic malignant syndrome, or clinically significant tardive dyskinesia as assessed by the investigator. It also excluded use of CYP2D6 and CYP3A4 inhibitors or CYP3A4 inducers within 14 days before dosing, with fluoxetine or fluoxetine/olanzapine requiring a 28-day washout, and these agents were not allowed during the trial or for 30 days after the last study dose.
Clinical Considerations
- This workflow applies to clinically stable adults with schizophrenia and does not address acute relapse treatment.
- The study excluded patients with treatment resistance, significant suicide risk, recent substance use disorder, and certain neurologic histories, so generalizability to those groups is limited.
- The trial was open-label and conducted only in the United States.
- Efficacy analyses were secondary and the study was not powered to detect statistically significant change from baseline in efficacy outcomes.
Bottom Line
Use aripiprazole 2-month ready-to-use 960 mg as a maintenance option for carefully selected, clinically stable adults with schizophrenia who can tolerate aripiprazole and do not have the exclusion features used in the trial.
